Extensive, late-stage radiopharmaceutical pipeline

Our core product pipeline, focused on prostate, renal (kidney), glioblastoma (brain) and hematologic cancers (bone marrow conditioning) is based on decades of clinical experience and real patient outcomes.

Our investigational diagnostic products have the potential to guide treatment decisions, while our therapeutic candidates have potential to deliver personalised precision medicine.